[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Oystershell NV\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":140},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,67,89,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642367","safety-efficacy-and-preventative-effect-of-a-head-lice-product-x92001483-vs-nix-creme-rinse-1-permethrin-100642367",false,"NCT07660354","Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).","In Vivo Testing : A Two-Arm, Randomized, Controlled, Investigator\u002FAssessor-Blinded, Comparative Study to Evaluate the Safety, Efficacy, and Preventative Effect of a Head Lice Physically Acting Product: 2 in 1 SHAMPOO EU VERSION (X92001483) vs NIX CREME RINSE (1% Permethrin) in Subjects With Head Lice.","Inclusion Criteria:\n\n1. Gender: male \u002F female.\n2. The subject or his\u002Fher parent\u002Flegal guardian (from age 12-17) must give written informed consent (after having been informed orally and by written text about the benefits and potential risks of the trial, as well as information regarding the insurance, taken out to cover the subjects participating in the study). A caregiver must sign an informed consent agreement for children not old enough to do so. Children aged 6-11 years of age will be administered a child's assent form. The subject or his\u002Fher parent\u002Flegal guardian must be capable of understanding and providing written informed consent.\n3. Age ≥ 1 year of age at the time of enrollment.\n4. Subject agree to not use any other anti-lice or preventative treatment or medicated hair grooming products for the duration of the study (through last visit day- Day 14).\n5. Subject must have an active head lice infestation defined as at least 5 live lice (adults and\u002For nymphs) and 5 live nits based on magnified observations, present on the scalp and\u002For hair, as determined by a trained evaluator.\n6. The subject is in good general health based on medical history.\n7. Female subjects of childbearing potential must have a negative pregnancy test at screening and agree to use a reliable method of birth control (as described in section 7.8) during duration of the study.\n8. The parent or legal guardian of a child subject must consent to the screening of other household members for head lice. If additional household members are found to have head lice and meet eligibility criteria, they must be enrolled in the study for all household members to qualify for participation.\n9. Have a single place of residence or agree to remain at the current residence for the duration of the study.\n10. Subject agrees not to additionally shampoo, wash, or rinse their hair or scalp for 24-hours post treatment.\n11. The subject agrees not to cut or chemically treat their hair while participating in the study.\n12. Subject agrees to follow all study instructions, including attending all follow-up appointments.\n\nExclusion Criteria:\n\n1. Application of any form of head lice treatment, whether prescription or over-the counter (OTC), or home remedy for 14 days prior to their screening visit (Visit 1).\n2. Application of any topical medication of any kind on the hair or scalp for a period of 48 hours prior to the screening visit.\n3. Use of systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results.\n4. Known skin allergies, multiple drug allergies or multiple allergies to cosmetic products.\n5. History of allergy or hypersensitivity to active ingredients, or constituents of the investigational or comparator products.\n6. Subject with any visible skin\u002Fscalp condition at the treatment site which, in the opinion of the investigative personnel, will interfere with the evaluation of the investigational product.\n7. Subjects with chronic scalp disorder.\n8. Subject or his\u002Fher legal guardian who, in the opinion of the investigative personnel, do not understand the subject requirements for study participations and\u002For may be likely to exhibit poor compliance with the required visits.\n9. Females who are pregnant or nursing.\n10. Hair longer than waist length.\n11. Subject suspected or known not to follow instructions\n12. Previous participation in this study or participation in any other investigational trial within the preceding 14 days.\n13. The subject is directly affiliated to the investigator site personnel and\u002For their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.\n14. The subject is an Oystershell employee or is an employee of a third-party organization involved in the study.\n15. People with dreadlocks or clips in hair that cannot be removed or a person who does not want to remove these.\n16. Hair that is too difficult to work with as assessed by the study staff.\n17. Families excluded where lice exist however a family member decline enrollment in the study.\n18. Subjects who are receiving, or are expected to receive, any antibiotic therapy during the study period will be excluded.\n19. No more than one working male subject per household may be excluded from evaluation if determined to be lice free by self-report or caregiver observation.\n20. All household members of the subject, other than excluded male adult, must be screened for head lice by a certified head lice professional. If additional household members are found to have head lice and meet the study criteria, they will be referred to LSRN Research and enrolled in study. If a household member declines enrollment, all family members will be excluded from the study.","ALL","1 Year",{"count":19,"type":20},98,"ESTIMATED","INTERVENTIONAL",[23],"NA","To compare the safety, effectiveness, and preventive benefits of a medical device (X92001483) against Nix Cream Rinse (1% Permethrin) in people with head lice",[26],"Lice; Head Lice",[28],"Head Lice Treatment","RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-22","ACTUAL",{"date":35,"type":33},"2026-05-01",{"date":37,"type":20},"2026-12",{"name":39,"class":40},"Oystershell NV","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100620278","evaluate-the-effectiveness-and-safety-of-a-cryogenic-pen-to-treat-skin-tags-versus-a-comparator-100620278","NCT07355543","Evaluate the Effectiveness and Safety of a Cryogenic Pen to Treat Skin Tags Versus a Comparator.","Prospective, Single Centre, Single-blinded, Randomized Clinical Investigation to Evaluate the Effectiveness and Safety of a Cryogenic Device to Treat Skin Tags Versus a Comparator Product.","Inclusion Criteria:\n\n1. Healthy subject.\n2. Sex: male or female.\n3. Age: more than 22 years old.\n4. Phototype: I to III according to Fitzpatrick.\n5. Subject presenting at least one skin tag that could be treated by the tested devices as evaluated by the investigator:\n\n   * Location: on the neck, chest, back, groin or underarm;\n   * Colour: skin tags must be similar in colour to the surrounding skin;\n   * Shape \\& Feel: skin tags must be soft and flexible.\n   * Size: 2 to 5 mm in size.\n6. Subject having given freely and expressly his\u002Fher informed consent.\n7. Subject who is able to comply with the study requirements, as defined in the present CIP, at the investigator's appreciation.\n8. Subject affiliated to a health social security system.\n9. Female of childbearing potential should use a contraceptive regimen recognized as effective since at least 12 weeks before screening visit and during all the study.\n\nExclusion Criteria:\n\n1. Pregnant or nursing woman or planning a pregnancy during the study.\n2. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.\n3. Subject in a social or sanitary establishment.\n4. Subject having received 6000 euros indemnities for participation in clinical research in the 12 previous months, including participation in the present study.\n5. Subject enrolled in another clinical trial or which exclusion period is not over.\n6. Member of the CRO or the centre staff.\n7. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.\n8. Subject suffering from a severe or progressive disease (including asthma and diabetes).\n9. Subject with immune deficiency or autoimmune disease.\n10. Subject suffering from an acute or cutaneous disease or any other cutaneous pathology.\n11. Subject with a history of skin cancer or pre-cancerous skin lesions.\n12. Subject with previous event of healing disorders such as hypertrophic or keloid scar, residual pigmentation etc.\n13. Subject with blood circulation or blood clotting problems including Raynaud's disease; blood dyscrasias of unknown origin; haemophilia subjects.\n14. Subject presenting skin growths such as birthmarks, moles, warts, or any other unusual-looking skin condition on the treated zone.\n15. Subject having thin, inflamed, damaged, irritated, itchy, infected, cut, grazed, diseased or red skin on and around the treated zone.\n16. Subject with molluscum contagiosum, blisters or any other vesicles on the skin on and around the treated zone.\n17. Subject with a known allergy to Chlorhexidine based antiseptic or to adhesives.\n18. Subject who already had an abnormal reaction to cold.\n19. Subject whose selected skin tag is bleeding or scratched.\n20. Subject whose skin tag is located on the face, scalp or mucosa, anus, genitals, buttocks, lips, eyelids or eyes.\n21. Subject undergoing a topical treatment on the test area or a systemic treatment:\n\n    * anti-inflammatory medication within 5 days prior to D0 visit,\n    * immunosuppressors and\u002For corticoids within 10 days prior to D0 visit,\n    * retinoids within 6 months prior to D0 visit,\n    * treatment with an action on coagulation within 1 week prior to D0 visit,\n    * any long-term medication stabilized for less than one month.\n22. Subject who received a treatment of any kind on the selected skin tag within 6 months prior to D0 visit.\n23. Intensive exposure to sunlight or UV-rays within the previous month and\u002For foreseen exposure of the treated zone during the study.","22 Years",{"count":51,"type":20},56,[23],"The purpose of this clinical investigation is to evaluate the effectiveness and safety of Nitrofreeze Skin Tag for the treatment of skin tags versus a comparator device (Scholl Freeze Away® Skin Tag Remover).",[55],"Skin Tags",[57,58],"NITROFREEZE SKIN TAG","SKIN TAG","2026-01-20",{"date":61,"type":33},"2026-01-21",{"date":63,"type":33},"2025-10-06",{"date":65,"type":20},"2026-01",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100611741","efficacy-and-safetyof-a-medical-device-with-a-physical-mode-of-action-x92001919-versus-paranix-anti-lice-shampoo-100611741","NCT07244523","Efficacy and Safetyof a Medical Device With a Physical Mode of Action (X92001919) Versus Paranix Anti-lice Shampoo.","Prospective, Comparative, Two-arms, Randomized, Controlled, Investigator\u002FAssessor-blinded Study for the Evaluation of the Efficacy and Safety of a Medical Device With a Physical Mode of Action (X92001919) Versus Paranic Anti-lice Shampoo on the Treatment of Head Lice Infestation.","Inclusion Criteria:\n\n* Healthy subject (except head lice infestation) based on medical history;\n* Gender: male or female;\n* Age: 2 years and above at the time of enrolment ;\n* Subject with a slight to moderate lice infestation (according to EU norms)\n* Subjects with various hair type (from 1 to 3C in the hair scale below) and hair length (from short to mid length hair, not exceeding shoulder)\n* Documented oral informed consent for all subjects, including minors, given freely and expressly before the start of the study\n* Written informed consent for subjects ≥18 years or legal guardian for subjects \\\u003C 18 years given freely and expressly before start of the study;\n* Written assent for subjects ≥12 to \\\u003C18 years.\n* Subject\u002FSubject's legal guardian is psychologically able to understand the study related information and to give written informed consent;\n* Females of childbearing potential must have a negative pregnancy test before the beginning of the study and agree to use a reliable method of birth control during the study.\n* Subject agrees not to cut or chemically treat their hair while participating in the study.\n* Subjects agrees not to use any other anti-lice treatment or medicated hair grooming products for the duration of the study.\n\nExclusion Criteria:\n\n* In terms of population\n\n  1. Pregnant (confirmed by pregnancy test at D0 for women of childbearing potential) or nursing woman or planning a pregnancy during the study;\n  2. Subject who had been deprived of their freedom by administrative or legal decision or adult subject who is under guardianship;\n  3. Subject in a social or sanitary establishment;\n  4. Subject in an exclusion period from a previous study or who is currently participating in another study on hair\u002Fscalp or who participated to another clinical study on hair\u002Fscalp within 3 months before first visit.\n  5. Subject suspected to be non-compliant according to the Investigator's judgment.\n  6. Subject with curly or frizzy hair (from 4A to 4C in the hair type scale above).\n  7. Subject with hair length below the shoulder.\n  8. Subjects with more than 24 lice on the head.\n* In terms of associated pathology 9. Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results.\n\n  10\\. Subject with a cutaneous disease on the studied zone (scalp and hair). 11. Subject with severe scratches or open wounds\u002Fskin damages on the scalp (lice bites allowed however).\n\n  12\\. Subject with a known or suspected allergy to any of the components\u002Fmaterials of the investigational products, anti-lice comb or post- treatment shampoo.\n\n  13\\. Subject who has diabetes (type 1 or 2). 14. Subject with known or suspected immune deficiency or autoimmune disease.\n* Relating to previous or ongoing treatment 15. Subject undergoing a topical treatment on the test area or a systemic treatment with:\n\n  * anti-inflammatory medication and\u002For anti-histamines during the previous 2 weeks and during the study;\n  * corticosteroids during the 2 previous weeks and during the study;\n  * retinoids and\u002For immunosuppressors during the 3 previous months and during the study;\n  * any medication stabilized for less than one month. 16. Subject who received an anti-lice treatment in the previous 2 months.","2 Years",{"count":76,"type":20},34,[23],"Comparison of the efficacy of a new medical device with a physical mode of action to Paranix anti-lice shampoo in the treatment of head lice infestation.",[26],"NOT_YET_RECRUITING","2025-11-17",{"date":83,"type":33},"2025-11-24",{"date":85,"type":20},"2026-02",{"date":87,"type":20},"2026-04",{"name":39,"class":40},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":41},"100607661","safety-and-efficacy-of-head-lice-treatments-elimax-green-lotion-and-walgreens-lice-killing-shampoo-100607661","NCT07191457","Safety and Efficacy of Head-lice Treatments Elimax Green Lotion and Walgreens Lice Killing Shampoo","In Vivo Testing: A Two-Arm, Randomized, Controlled, Investigator\u002FAssessor-Blinded, Comparative Study to Evaluate the Safety and Efficacy of a Head Lice Physically Acting Product: ELIMAX GREEN LOTION EMOGREEN (X92001752) vs Walgreens Lice Killing Shampoo (Piperonyl Butoxide (4%),Pyrethrum Extract (Equivalent to 0.33% Pyrethrins)) in Subjects With Head Lice.","Inclusion Criteria:\n\n* Gender: male \u002F female.\n* Female subjects with childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control (as described in section7.8) or remain\n* Age ≥ 6 months of age at the time of enrollment.\n* Subject must have an active head lice infestation defined as at least 5 live lice (adults and\u002For nymphs) and 5 live nits based on magnified observations, present on the scalp and\u002For hair, as determined by a trained evaluator.\n* Subject is in good general health based on medical history.\n* Following application per designated product timeline shampoo hair using Johnson's baby shampoo (See figure 4 for shampoo image) to rinse out the product according to the study product its IFU. Subject agrees not to additionally shampoo, wash, or rinse their hair or scalp for 24-hours post treatment.\n* The subject agrees not to cut or chemically treat their hair while participating in the study.\n* Subject agrees to follow all study instructions, including attending all follow-up appointments.\n* Agree to not use any other anti-lice treatment or medicated hair grooming products for the duration of the study (through Day 10 visit).\n* The parent or legal guardian of a child must be willing to have other family members screened for head lice. If other household members are found to have head lice and are eligible, they must be either enrolled in the study OR receive the standard of care at the site and in the same manner as study participants.\n* Have a single place of residence or agree to remain at the current residence for the duration of the study.\n* The subject or his\u002Fher parent\u002Flegal guardian (from age 12-17), must give written informed consent, after having been informed orally and by written text about the benefits and potential risks of the trial, as well as information regarding the insurance, taken out to cover the subjects participating in the study. A caregiver must sign an informed consent agreement for children not old enough to do so. Children aged 6-11 years of age will be administered a child's assent form. Subject or his\u002Fher parent\u002Flegal guardian must be capable of understanding and providing written informed consent.\n\nExclusion Criteria:\n\n* Application of any form of head lice treatment, whether prescription or over-thecounter (OTC), or home remedy for 14 days prior to their screening visit (Visit\n* Application of any topical medication of any kind on the hair or scalp for a period of 48 hours prior to the screening visit.\n* Use of systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results.\n* Known skin allergies, multiple drug allergies or multiple allergies to cosmetic products.\n* History of allergy or hypersensitivity to active ingredients, or constituents of the test products.\n* Subject with any visible skin\u002Fscalp condition at the treatment site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test product.\n* Subjects with chronic scalp disorder.\n* Subject or his\u002Fher legal guardian who, in the opinion of the investigative personnel, do not understand the subject requirements for study participations and\u002For may be likely to exhibit poor compliance with the required visits.\n* Females who are pregnant or nursing.\n* Hair longer than waist length.\n* Subject suspected or known not to follow instructions\n* Previous participation in this study or participation in any other investigational trial within the preceding 14 days.\n* The subject is directly affiliated to the investigator site personnel and\u002For their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.\n* The subject is an Oystershell employee or is an employee of a third-party organizations involved in the study.\n* Exclude families with 4 or more household members.\n* People with dreadlocks or clip in hair that cannot be removed or a person who does not want to remove these.\n* Hair that is too difficult to work with, assessed by the study staff.\n* Families excluded where lice exist however family member declines enrollment in the study.\n* Subjects who are receiving, or are expected to receive, any antibiotic therapy during the study period will be excluded.\n* No more than one working subject per household may be excluded from evaluation if he is assessed as being lice by himself or caregiver. Only working male can be excluded from evaluation if individual is bald or hair no longer than half inch and deemed lice free by himself or another adult.\n* All household members of the subject, other than excluded male adult, must be screened for head lice by a licenced head lice professional. If additional household members are found to have head lice and meet the study criteria, they will be referred to LSRN Research and enrolled in study. If a household member declines enrollment, all family members will be excluded from the study.","6 Months",{"count":98,"type":20},86,[23],"Compare efficacy and safety of Elimax Green Lotion Emogreen (RID SUper Max Solution) to that of Walgreens Lice Killing Shampoo against headlice in infested individuals. Involved subjects aged 6 months and older, of both genders, with a confirmed diagnosis of head lice infestation are included. Local and global tolerability, skin and eye irritation are monitored throughout the study. Any adverse events will be monitored and recorded.",[102],"Head Lice",[102,104,105,106,107],"Walgreens Lice Killing Shampoo","Elimax Green Lotion Emogreen","RID Super Max Solution","Pyrethrum","2025-09-17",{"date":110,"type":33},"2025-09-24",{"date":112,"type":20},"2025-10-02",{"date":114,"type":20},"2026-04-01",{"name":39,"class":40},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":139,"locationsCount":41},"100569100","clinical-investigation-for-the-evaluation-of-efficacy-and-safety-of-two-products-for-the-treatment-of-onychomycosis-100569100","NCT06689852","CLINICAL INVESTIGATION FOR THE EVALUATION OF EFFICACY AND SAFETY OF TWO PRODUCTS FOR THE TREATMENT OF ONYCHOMYCOSIS","MULTICENTRIC, RANDOMIZED, EVALUATOR BLINDED CLINICAL INVESTIGATION FOR THE EVALUATION OF EFFICACY AND SAFETY OF TWO PRODUCTS FOR THE TREATMENT OF ONYCHOMYCOSIS","Inclusion Criteria:\n\n* 1\\. Patient having given freely her\u002Fhis informed, written consent. 2. Patient having a good general health. 3. Age: between 18 and 70 years; 4. Patient with superficial onychomycosis on at least one great toenail or fingernail (for at least 10% in each arm) or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement \\<2\u002F3 of the tablets).\n\n  5\\. Patient with positive KOH staining. 6. Patient cooperative and aware of the products modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.\n\n  7\\. Patient being psychologically able to understand information and to give their\u002Fhis\u002Fher consent.\n\n  8\\. Patient having stopped any systemic antifungal treatment since at least 6 months before screening and\u002For any topical antifungal treatment since at least 3 months before screening.\n\n  9\\. Patient who agree to refrain from receiving pedicure\u002Fmanicure, artificial nails and\u002For cosmetic nail varnish or other medication on the nail being treated for the entire study duration.\n\n  10\\. Female of childbearing potential should use a contraceptive regimen recognized as effective since at least 12 weeks before screening visit, during all the study and at least 1 month after study end.\n\nExclusion Criteria:\n\n\\- 1. Pregnant, breastfeeding woman or woman planning a pregnancy during the study; 2. Patient considered by the investigator likely to be non-compliant with the protocol. 3. Patient enrolled in another clinical trial or which exclusion period is not over. 4. Patient with a condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk; 5. Patient suffering from a severe or progressive disease (to investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, HIV, psoriasis, lichen planus, immunosuppressive pathology… 6. Patient having a known allergy or hypersensitivity to one of the constituents of the tested products.\n\n7\\. Patient with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis…).","18 Years","70 Years",{"count":126,"type":20},88,[23],"The efficacy and safety of ENRICHED (X92001591) will be evaluated in a multicentric, randomized, evaluator blinded clinical investigation in 88 patients.",[130],"Onychomycosis",[132],"onychomycosis","2025-09-02",{"date":135,"type":33},"2025-09-03",{"date":137,"type":33},"2024-10-30",{"date":87,"type":20},{"name":39,"class":40},""]